Tham khảo Foscarnet

  1. ↑ Long, Sarah S.; Pickering, Larry K.; Prober, Charles G. (2012). Principles and Practice of Pediatric Infectious Disease (bằng tiếng Anh). Elsevier Health Sciences. tr. 1502. ISBN 1437727026.
  2. ↑ Canestri A, Ghosn J, Wirden M (2006). “Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance”. Antivir. Ther. (Lond.). 11 (5): 561–6. PMID 16964823. Đã bỏ qua tham số không rõ |displayauthors= (gợi ý |display-authors=) (trợ giúp)
  3. ↑ Mathiesen S, Dam E, Roge B (2007). “Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1”. Antivir. Ther. (Lond.). 12 (3): 335–43. PMID 17591023. Đã bỏ qua tham số không rõ |displayauthors= (gợi ý |display-authors=) (trợ giúp)
  4. ↑ Meyer PR, Rutvisuttinunt W, Matsuura SE, So AG, Scott WA (2007). “Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet”. J. Mol. Biol. 369 (1): 41–54. doi:10.1016/j.jmb.2007.03.006. PMC 1986715. PMID 17400246.
  5. ↑ Meyer PR, Rutvisuttinunt W, Matsuura SE, So AG, Scott WA (tháng 5 năm 2007). “Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet”. J. Mol. Biol. 369 (1): 41–54. doi:10.1016/j.jmb.2007.03.006. PMC 1986715. PMID 17400246.
  6. ↑ Bonnafous P, Naesens L, Petrella S (2007). “Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet”. Antivir. Ther. (Lond.). 12 (6): 877–88. PMID 17926642. Đã bỏ qua tham số không rõ |displayauthors= (gợi ý |display-authors=) (trợ giúp)
  7. ↑ Tchesnokov EP, Gilbert C, Boivin G, Götte M (tháng 2 năm 2006). “Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet”. J. Virol. 80 (3): 1440–50. doi:10.1128/JVI.80.3.1440-1450.2006. PMC 1346920. PMID 16415021.